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20Computationally motivated synthesis and enzyme
kinetic evaluation of N-(b-D-glucopyranosyl)-
1,2,4-triazolecarboxamides as glycogen
phosphorylase inhibitors†
Jaida Begum,a Gergely Varga,b Tibor Docsa,c Pa´l Gergely,c Joseph M. Hayes,*a
La´szlo´ Juha´sz*b and La´szlo´ Somsa´k*b
Following our recent study of N-(b-D-glucopyranosyl)oxadiazolecarboxamides (Polya´k et al., Biorg. Med.
Chem. 2013, 21, 5738) revealed as moderate inhibitors of glycogen phosphorylase (GP), in silico docking
calculations using Glide have been performed on N-(b-D-glucopyranosyl)-1,2,4-triazolecarboxamides
with diﬀerent aryl substituents predicting more favorable binding at GP. The ligands were subsequently
synthesized in moderate yields using N-(2,3,4,6-tetra-O-acetyl-b-D-glucopyranosyl)-tetrazole-5-
carboxamide as starting material. Kinetics experiments against rabbit muscle glycogen phosphorylase b
(RMGPb) revealed the ligands to be low mM GP inhibitors; the phenyl analogue (Ki ¼ 1 mM) is one of the
most potent N-(b-D-glucopyranosyl)-heteroaryl-carboxamide-type inhibitors of the GP catalytic site
discovered to date. Based on QM and QM/MM calculations, the potency of the ligands is predicted to
arise from favorable intra- and intermolecular hydrogen bonds formed by the most stable solution phase
tautomeric (t2) state of the 1,2,4-triazole in a conformationally dynamic system. ADMET property
predictions revealed the compounds to have promising pharmacokinetic properties without any toxicity.
This study highlights the beneﬁts of a computationally led approach to GP inhibitor design.25
30
35
40Introduction
Type 2 diabetes mellitus (T2DM) is characterized by hypergly-
cemia and peripheral insulin resistance, and represents more
than 90% of all diabetic cases. The signicant increase in the
global incidence of diabetes is a major cause for concern,
having doubled over the previous 3 decades to 347 million
people in 2008.1 Without adequate control of blood glucose
levels, T2DM has several long term complications such as
neuropathy and nephropathy, as well as an increased risk of
blindness and cardiovascular disease.2 Glycogen phosphorylase
(GP; EC 2.4.1.1) is a validated target for T2DM having a direct
inuence on blood glucose levels through the glycogenolysis
pathway.3 It is an allosteric enzyme with a number of diﬀerent
binding sites,4,5 the catalytic, allosteric, new allosteric,emistry, University of Central Lancashire,
n.ac.uk; Fax: +44 (0)172894981; Tel: +44
ty of Debrecen, POB 20, H-4010 Debrecen,
ideb.hu; somsak.laszlo@science.unideb.
ext. 22474; +36 52512900 ext. 22348
and Health Science Centre, University of
Hungary
tion (ESI) available. See DOI:
hemistry 2014
45
50inhibitor, glycogen storage, benzimiadazole6 and the very
recently identied quercetin binding site.7 Signicant eﬀorts
have been aﬀorded to the design of GP inhibitors in recent
years, with catalytic site inhibitors the most explored.4,8,9 The
physiological inhibitor of GP is a-D-glucose (Ki¼ 1.7 mM), but b-
substitutions at the anomeric carbon of D-glucose have led to
the most eﬀective GP catalytic site inhibitors and have
demonstrated blood sugar lowering eﬀects in vivo.10,11
An evaluation of the current status of b-D-glucopyranosyl
analogues as GP inhibitors can be found in recent reviews.4,8
The four most potent discovered to date are shown in Fig. 1, all
of which possess a 2-naphthyl moiety exploiting favorable
interaction of aryl groups in the catalytic b-cavity, a pocket lined
by both polar and non-polar groups. In general, the 2-naphthyl
moiety has proved the most eﬀective in terms of potency, but
our recent studies on N-(b-D-glucopyranosyl)-oxadiazole-
carboxamides with linkers 2–4 (Table 1) have revealed that
this is not always the case.16 However, these ligands only
demonstrated moderate potency at best, 2b and 3c the most
potent with Ki's  30 mM. The 1,2,4-triazole moiety in the form
of 3-(b-D-glucopyranosyl)-5-substituted-1,2,4-triazoles has very
recently revealed some of the most potent inhibitors of the GP
catalytic site,13,14 with the 2-naphthyl derivative (1c in Fig. 1) the
most potent. In the current work, we have investigated N-(b-D-
glucopyranosyl)-3-substituted-1,2,4-triazole-5-carboxamides,Med. Chem. Commun., 2014, xx, 1–10 | 1
Fig. 1 The four most potent glucose analogue inhibitors of GP
discovered to date (1a,12 1b,5 1c13,14 and 1d15) together with their Ki's for
RMGPb inhibition. All ligands possess a 2-naphthyl substituent
exploiting favorable interactions in the GP catalytic site b-cavity.
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25replacing the oxadiazole moiety of linkers 2–4 with a 1,2,4-tri-
azole (5, Table 1) in an attempt to improve ligand potency. Prior
to undertaking synthesis, in silico calculations in the form
of Glide docking, quantum mechanics (QM) and quantum
mechanics/molecular mechanics (QM/MM) calculations
were performed to probe the binding potential of these ligands
at GP.Table 1 Inhibition constants (Ki [mM], RMGPb) and Emodel docking sco
boxamides 2–4, and N-(b-D-glucopyranosyl)-1,2,4-triazolecarboxamides
calculated using eqn (1)
Scaﬀold
Ar
Linker a
Oxadiazoles
2
54
9
3
13
1
4
10
1
1,2,4-Triazoles
5
1
1
a No inhibition. b Calculated from the IC50 values by the Cheng–Prusoﬀ e
2 | Med. Chem. Commun., 2014, xx, 1–10Results & discussion
In silico binding studies
All ligands in Table 1 were prepared for calculations using
Maestro and the LigPrep 2.5 program18 generating minimized
favorable tautomeric and ionization states of all ligands at pH¼
7 2. All ligands were assigned as neutral, but three tautomeric
forms (t1, t2 and t3) of the 1,2,4-triazole (linker 5) were
produced, with t1 and t2 the most probable based on LigPrep
with Epik (Table 2).18 Monte Carlo conformational searches on
models of ligands 5 and its three tautomers t1–t3 were per-
formed followed by Jaguar 8.0 density functional theory (DFT)
with M06-2X19 and the 6-31+G* basis set20,21(M06-2X/6-31+G*),
and yielded the conformations shown in Table 2. Higher level
M06-2X/cc-pVTZ++22 single point energy (SPE) calculations in
gas and solution phase at these geometries revealed that while
t1 is the most favored in the gas phase by 6 kcal mol1, t2 is
clearly preferred in solution (by 9 kcal mol1). This is in
contrast to the tautomeric probabilities from LigPrep/Epik,
highlighting the value of a QM approach to such analysis.
Tautomer t2 also allows for approximately two equally stable
conformations (u ¼ 0 or 180) in the free unbound solvated
state, as dened by the dihedral angle u dened in Table 2. The
molecular electrostatic potentials (MESPs) are shown in Fig. 2.
For tautomer t2, the two diﬀerent conformations have littleres from Glide (in italics) for N-(b-D-glucopyranosyl)-oxadiazole-car-
5. The normalized values of Emodel are also shown in parentheses, as
b C
5b 30 172b
2.31(3.69) 116.15(4.01) 112.17(3.87)
6b N.I.a 33
00.68(4.03) 115.78(3.99) 117.65(4.06)
4 N.I.a 145b
00.15(4.01) 111.92(3.86) 113.96(3.93)
9.2 —
02.34(4.09) 116.52(4.02) 120.43(4.15)
quation: Ki ¼ IC50/(1 + [S]/Km).17
This journal is © The Royal Society of Chemistry 2014
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Table 2 Comparison of the relative energies (kcal mol1) of diﬀerent tautomers and conformations of the 1,2,4-triazole (linker 5) for models of
the N-(b-D-glucopyranosyl)-1,2,4-triazolecarboxamides, as calculated using density functional theory. For simplicity and speed, in the calcu-
lations the b-D-glucopyranose was replaced by a methyl group and a phenyl used for the Ar group. Geometries used in calculations were from
M06-2X/6-31+G* optimizationsa
Tautomer
Dihedral
angle ub ()
LigPrep tautomer
probability
Gas phasec Solution phase
c,d
M06-2X/6-31+G* M06-2X/cc-pVTZ++ M06-2X/cc-pVTZ++
t1
180 0.487 0.0(0.0)e 0.0 8.6
t2
0
0.487
6.5(7.2)e 5.9 0.5
180 5.9(6.9)e 5.3 0.0
t3
0 0.027 5.9(6.4)e 5.5 9.0
a Tautomeric states were determined using LigPrep.18 MacroModel 9.9 (ref. 18) conformational searches were used to locate the above favorable
conformations of the compounds, which were then used in the QM optimizations. The dihedral angle u adopted by the atoms 1, 2, 3, 4 for
rotation around the 2,3 bond is key to the conformational properties. b Values for the minima from the M06-2X/6-31+G* optimizations. c Single
point energy calculations at the optimized M06-2X/6-31+G* geometries. d Continuum treatment of solvation which involved accurate numerical
solution of the Poisson–Boltzmann (PBF) equation.24,25 e Relative Gibbs free energies given in parentheses.
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55eﬀect on the ESPs of the amide. However, the ESP in the space
around a gas phase molecule is a key factor in determining its
ability to accept a proton; in this regard, for t2 (u ¼ 180) the
maximum ESP of the triazole NH nitrogen (62.55 kcal mol1)
and minimum ESP of the connected N (50.84 kcal mol1) is
consistent with H+ migration to form the most stable t1
tautomer in the gas phase (Table 2). The intra-molecular NH
(amide) and triazole N (lone pair) contacts for the tautomers can
only loosely be classied as hydrogen bonds under the current
IUPAC guidelines23 (donor angles are 103–105, hence less
than the preferred >110), however, there is evidence of charge
transfer in the case of t1 and t2 tautomers where the magni-
tudes of the potential at the N are less 15 kcal mol1. In any
case, favourable electrostatic stabilization occurs between these
atoms and the contacts are present in all free state conforma-
tions. The conformational exibility and MESP of t2 compared
to the other tautomers become important factors when we
consider the binding at GPb.
Docking calculations were performed using Glide 5.8 in
extra-precision (XP) mode,18,26 a docking algorithm which has
proved eﬀective in previous GPb catalytic site studies.15,27,28 The
predictive capability of Glide-XP in the current study was
measured by the ability of the algorithm to reproduce the trends
in the kinetics results for the N-(b-D-glucopyranosyl)-oxadiazole-
carboxamides with linkers 2–4. The results are shown in Table
1, with the most consistent results obtained using the EmodelThis journal is © The Royal Society of Chemistry 2014scoring function which combines GlideScore, the non-bonded
interaction energy and the excess internal energy of the gener-
ated ligand conformation. Non-bonded interactions in a
scoring function are typically calculated as a sum of pair-wise
interactions. Hence, a larger compound oen receives a more
favorable score than a smaller compound. In order to overcome
this bias, a number of diﬀerent normalization and scaling
approaches have been proposed.29,30 Given that the aforemen-
tioned trend appeared to occur for our training set ligands, we
used the following equation to account for the diﬀerent sizes of
our aryl substituents (phenyl versus naphthyl):
Emodelnorm ¼ Emodel/number of heavy atoms (1)
On initial inspection of Table 1, the predictive capability of
the docking does not appear obvious. For example, the score for
3b is clearly over-estimated. However, a reasonable correlation
R2 ¼ 0.67 between predicted (Emodelnorm) and experimental
(ln Ki) binding strengths was obtained. Further, the most
favorable aryl group for each of the linkers 2–4 was correctly
predicted: 2-naphthalene (2b) in the case of 2, 1-naphthalene
(3c) in the case of 3 (1-naphthalene) and phenyl (4a) in the case
of 4. In terms of our key objective, to accurately predict the
potential of linker 5, we noted that the most favorable linker
(from 2–4) for each aryl group was also correctly identied:
linker 2 in the case of 2-naphthalene (Ki¼ 30 mM), linker 3 for 1-Med. Chem. Commun., 2014, xx, 1–10 | 3
Fig. 2 Molecular electrostatic potential (MESPs) can be used to provide insight into a number of hydrogen bonding phenomena. Shown are the
results of MESP calculations (M06-2X/6-31+G*) on a model of the isolated 5a ligand (Me groups instead of glucopyranose) in its diﬀerent
tautomeric forms and most stable conformations (Table 2). The electrostatic potentials are mapped onto the electron density surface for each
molecule. Only the ESP range of 50 to 50 kcal mol1 is used for a better visual demonstration of the tautomeric eﬀects; actual minimum–
maximum ESP values were55.4 to 63.7 kcal mol1 obtained for the t2 tautomer. The minimum or maximum local electrostatic potential values
(kcal mol1) for the relevant atoms are also shown.
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35naphthalene (Ki ¼ 33 mM), and for phenyl the linkers 3 and 4
were predicted to have similar eﬃciency in line with kinetics
(Ki's ¼ 104–136 mM). Encouraged by this, we then noted that for
each of the phenyl, 1- and 2-naphthalence substituents, linker 5
was predicted to give rise to more potent ligands.
Despite their obvious importance, tautomeric states are still
oen not accurately considered in computer-aided drug design
eﬀorts.31 The most favorable tautomeric state for binding of
ligands 5a–5c based on Emodel docking scores was t2 for bothTable 3 QM/MM gas and solution phase relative energies (kcal mol1) fo
diﬀerent tautomeric forms as described in the text. The corresponding E
Ligand Tautomera Emodel (Emodelnorm)
b
5a t1 99.8 (3.99)
t1 93.9 (3.76)
t2 102.3 (4.09)
t2 97.1 (3.88)
t3 91.0 (3.64)
5b t1 116.5 (4.02)
t2 115.4 (3.98)
t3 115.9 (4.00)
5c t1 114.3 (3.94)
t2 120.4 (4.15)
t2 114.6 (3.95)
t3 112.2 (3.87)
t3 110.5 (3.81)
a c.f. Table 2. b Normalized values as calculated using eqn (1). c Numberin
4 | Med. Chem. Commun., 2014, xx, 1–105a and 5c, and t1 for 5b (Table 3). The potential of using the
lowest QM/MM complex energy for protein–ligand docking pose
selection has recently been highlighted, where QM/MM ener-
gies were used to re-rank docking poses and compared with
their native crystallographic binding modes.32 Accordingly, to
more accurately probe the binding of 5a–5c and its diﬀerent
tautomers at GP, QM/MM optimizations with QSite 5.8 (ref. 18)
were performed on the Glide docking poses (Table 3). M06-2X/6-
31+G* was used for the QM region (the ligands), while the GPbr the optimized Glide docking poses of ligands 5a–5c considering the
model docking scores are also shown
u dihedral anglec ()
QM/MM relative energies
Gas phase Solution phase
34.3 16.6 18.1
178.0 7.7 19.6
19.7 3.8 0.0
176.7 0.0 10.7
3.5 14.5 13.3
33.3 14.5 15.8
10.1 0.0 0.0
3.2 13.0 8.9
16.2 18.9 16.5
43.3 6.5 1.3
10.7 0.0 0.0
0.5 13.8 13.1
154.9 11.8 6.4
g scheme for dihedral angle u as shown in Table 2.
This journal is © The Royal Society of Chemistry 2014
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30protein was described using MM with the OPLS-AA(2005)
forceeld,33 with otherwise default options. Solution phase
energies at the optimum geometries were then obtained,
employing a self-consistent reaction eld (SCRF) continuum
treatment for water solvation eﬀects and which involved accu-
rate numerical solution of the Poisson–Boltzmann (PBF) equa-
tion (M06-2X/6-31+G* + PBF).24,25 The results of the QM/MM
calculations (Table 3) revealed the most stable free state solu-
tion phase t2 tautomer of 5a–5c to also form the most favorable
complexes with GPb, in both gas and solution phases. From the
MESPs (Fig. 2) also, the t2 maximum and minimum atomic
ESPs of the triazole NH nitrogen and amide CO oxygen (both
conformations) are indicative of greater H-bond acceptor and
donor capabilities,34,35 respectively, for binding at GPb
compared to the other tautomers, although the value of ESP
maxima on molecular surfaces for predicting hydrogen bond
acidity has recently been questioned.36
For the GPb–5a complex (Fig. 3), as well as forming the
standard hydrogen bonding interactions from the b-D-gluco-
pyranosyl hydroxyl groups and a hydrogen bond from the car-
boxamide carbonyl O with the Leu136 backbone NH, through
rotation around the dihedral angle u the 1,2,4-triazole in its
favored solution phase t2 tautomeric form has the potential to
hydrogen bond with the Asp339 carboxylate on one side of the b-
cavity (water-bridged), and on the other side directly with the
Asp283 backbone O (u  50). If u  0 or u  180, although
the 1,2,4-triazole NH forms no direct hydrogen bonds with GPb,
there are favorable intra-molecular interactions from the car-
boxamide NH with the lone pair of electrons on a triazole N
atom for both conformations, as mentioned earlier for the free
state ligand (Fig. 2). The smaller Ar group (phenyl) of 5a alsoFig. 3 The lowest solution phase energy pose of ligand 5a (tautomer t2
using QM/MM and described in the text.
This journal is © The Royal Society of Chemistry 2014permits a ipped 1,2,4-triazole conformation (u ¼ 176.7)
shown in Fig. 4, where the triazole NH is a little longer than
hydrogen bonding distance from the Glu88 sidechain carbox-
ylate (distance  3.3 A˚). Hence, 5a in its t2 tautomeric state
exhibits considerable conformational exibility while bound at
GPb (favorable in terms of entropy). The 1,2,4-triazole has either
intra- and intermolecular hydrogen bonding potential in these
diﬀerent conformations; while CH–p interactions from the
Asp283 CH to the ligand Ar (phenyl) group can further stabilize
the GPb–5a complex (Fig. 3). For the binding of ligand 5b
(Fig. 5), interactions are similar to that as described for 5a in
Fig. 3, except the 2-naphthalene group extends deeper into the
b-cavity. However, the larger size of this Ar group limits some-
what the conformational versatility (u dihedral angle) of the
ligand, and it has much fewer poses compared to either 5a and
5c (Table 3). For 5c, the orientation of the 1-naphthalene allows
for greater conformational exibility in the GPb binding site
compared to its 2-naphthalene equivalent, and indeed the t3
tautomer is able to adopt a pose (u ¼ 154.9; Table 3) similar
to that shown for 5a in Fig. 3, with a ip in the 1,2,4-triazole.Synthesis
Based on the computational results, synthesis of the ligands
was considered worthwhile. Several methods have been pub-
lished for the preparation of 3,5-disubstituted 1,2,4-triazoles.37
While acyl-amidrazones (prepared from amides, thioamides,
nitriles, or amidines) could be transformed into the desired
triazoles under thermal conditions,37–39 the cycloaddition of
nitriles with nitrile-imines or nitrile-iminium ions gave 2,3,5-
trisubstituted 1,2,4-triazoles in moderate to good yields.40–43 The) bound at GPb with a dihedral angle (u ¼ 19.7; Table 3), as calculated
Med. Chem. Commun., 2014, xx, 1–10 | 5
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Fig. 4 The ﬂipped 1,2,4-triazole binding conformation of tautomer t2 of 5a at GPb (dihedral angle u¼176.7; Table 3), as calculated using QM/
MM and described in the text. The tautomeric t2 state allows for favorable intra-molecular hydrogen bond contacts between the carboxamide
NH and a 1,2,4-triazole N when u is close to 0 (Fig. 2) or ﬂipped (above). In the ﬂipped conformation, the 1,2,4-triazole NH is close to hydrogen
bonding distance with the Glu88 carboxylate.
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reaction of 5-substituted tetrazoles with imidoyl chlorides
(easily obtained from the corresponding amides by SOCl2) gave
3,4,5-trisubstituted 1,2,4-triazoles in good yields.44,45Fig. 5 The lowest solution phase energy pose of ligand 5b (tautomer t2) b
MM as described in the text.
6 | Med. Chem. Commun., 2014, xx, 1–10This latter method was extensively applied for the preparation
of 3-(C-glycosyl)-5-substituted-1,2,4-triazoles in our group.13 The
predicted target compounds of this study (5a,b) have beenound at GPb (dihedral angle u¼10.1; Table 3), calculated using QM/
This journal is © The Royal Society of Chemistry 2014
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Scheme 1 Synthesis of the predicted molecules 5a and 5b.
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25prepared using this methodology starting from tetrazole 6 (ref. 16)
as shown in Scheme 1. The imidoyl chlorides 10a,b and prepared
from N-benzyl-amides 9a,b as described earlier,13 were reacted
with tetrazole 6without any purication to give the corresponding
4-benzyl-N-(2,3,4,6-tetra-O-acetyl-b-D-glucopyranosyl)-5-aryl-1,2,4-
triazole-3-carboxamides 11a,b in moderate yields. In the case of
the 1-naphthyl derivative 5c, the formation of 11c from 10c was
unsuccessful, no transformation was detected and the desiredTable 4 Results of ADMET property predictions for the diﬀerent tautome
(5a–5c) studied in this worka
Inhibitor/
tautomer
Lipinski's rule of ve and violations
(V)b
V
Jorgensen's rul
violations (V)b
Mr [Da]
(<500)
HBDg
(#5)
HBAh
(#10)
log P(o/w)
(<5)
Caco-2i
[nm s1] (>22)
5a
t1 350.3 6 10 1.6 1 19.2*
t2 350.3 6 10 1.1 1 19.2*
t3 350.3 6 10 1.4 1 18.9*
5b
t1 400.4 6 10 0.8 1 19.2*
t2 400.4 6 10 0.3 1 19.2*
t3 400.4 6 10 0.6 1 19.0*
5c
t1 400.4 6 10 0.8 1 18.2*
t2 400.4 6 10 0.4 1 18.8*
t3 400.4 6 10 0.7 1 18.3*
Rangek 130–
725
0–6 2–20 2.0–
6.5
— <25 poor
>500 great
a ADMET data calculated using Qikprop 3.5;18 predicted properties outside
as listed in the columns, with any violations of the rules highlighted in ita
atoms; recommended PSA < 140 A˚2 according to Veber et al.54 d log Khsa:
brain barrier coeﬃcient. f Toxicity structural warnings from FAF-Drugs2
acceptors. i Caco-2 cell permeability. j Number of primary metabolites. k R
This journal is © The Royal Society of Chemistry 2014compound has not been synthesized yet using any other
synthetic methods.
The protecting groups were cleaved in a two-steps procedure.
The N-benzyl group of 11a,b was removed rst by catalytic
hydrogenation in excellent yields (94 and 85%). Subsequently,
O-deacetylation was eﬀected by the Zemple´n method to give
fully deprotected N-(b-D-glucopyranosyl)-5-aryl-1,2,4-triazole-3-
carboxamides 5a,b.rs of theN-(b-D-glucopyranosyl)-1,2,4-triazolecarboxamides inhibitors
e of three and
V
PSA [A˚2]c
log Khsa
d log BBe TSWf
log S
(>5.7) NMPj (<7) (<140 A˚2)
2.7 5 1 173.3 1.02 2.8 —
2.8 5 1 173.3 0.93 2.8 —
2.8 5 1 173.4 0.97 2.8 —
3.4 5 1 173.3 0.85 2.9 —
3.6 5 1 173.2 0.72 2.9 —
3.6 5 1 173.4 0.80 2.9 —
3.4 5 1 174.7 0.85 2.9 —
3.6 5 1 174.2 0.72 2.9 —
3.5 5 1 174.6 0.80 2.9 —
6.5–
0.5
1–8 — 7–200 1.5–
1.5
3.0–
1.2
—
the range for 95% of known drugs indicated with an asterisk (*). b Rules
lics. c PSA represents the van der Waals (polar) surface areas of N and O
predicted binding to human serum albumin. e log BB: predicted blood-
.48 g Number of hydrogen bond donors. h Number of hydrogen bond
ange for 95% of known drugs.18
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1
5
10Enzyme kinetics
The inhibition constants (Ki) against rabbit muscle glycogen
phosphorylase b (RMGPb) of compounds 5a,b were determined
according to the protocol described earlier.46 The results are
summarized in Table 1 together with the Ki's of 1,2,4- and 1,3,4-
oxadiazole-carboxamide type inhibitors. As the data shows, the
1,2,4-triazole analogues 5a (Ki ¼ 1 mM) and 5b (Ki ¼ 9.2 mM) are
more potent inhibitors than the oxadiazole analogues, consis-
tent with our computational predictions for favorable binding
at GPb.15
20
25
30
35
40
45Pharmacokinetic predictions
The early evaluation of the pharmacokinetic properties of lead
compounds in drug design eﬀorts is desirable due to the
potential for failure in late stage clinical trials. Accordingly, the
absorption, distribution, metabolism and excretion (ADME)
properties of 5a–5c were predicted using the QikProp 3.5
program in normal mode.18 Toxicity is the leading cause of drug
attrition in clinical trials, together with lack of eﬃcacy.47 The
FAF-Drugs2 server was used to extract any potential toxicity
structural warnings.48 Results are shown in Table 4.
An orally active drug should have no more than one violation
of Lipinski's ‘rule of ve’,49 while for Jorgensen's ‘rule of
three’50,51 more drug-like molecules have fewer violations. The
N-(b-D-glucopyranosyl)-1,2,4-triazolecarboxamides 5a–5c had
only one violation of each. The Lipinski violation is due to too
many hydrogen bond donors (HBDs), 6 instead of #5 in each
case, but this is still within the range for 95% of known drugs
and consistent with some recent ‘beyond rule of ve’
studies.52,53 In terms of Jorgensen's rules, the Caco-2 cell
permeability (>22 nm s1) is violated for the ligands (19 nm
s1), where previously we noted that the sensitive balance
between adequate lipophilicity and solubility may need atten-
tion in lead optimization of heterocyclic derivatives conjugated
to glucose.16 Meanwhile, the log Khsa's (degree of human serum
albumin aﬀecting bioavailability) is 0.9 to 0.7 and within
the range for 95% of known drugs (1.5 to 1.5), while the log BB
(blood-brain barrier coeﬃcients) values (2.9 to 2.8) are also
within the desirable range (3.0 to 1.2). Importantly, there were
no toxicity structural warnings for the ligands from FAF-Drugs2.
Overall, the pharmacokinetic results are similar with the results
for the N-(b-D-glucopyranosyl)-oxadiazole-carboxamides previ-
ously reported.16 However, in terms of pharmacodynamics the
5a,b ligands proved via kinetics experiments to be much more
potent inhibitors of GP.50
55Experimental
Computational details (additional)
Free ligand calculations. To determine the important (low
energy) tautomeric forms/conformations of the model ligands 5
(Table 2), 1000 steps of the Monte Carlo Multiple Minima
(MCMM) method were performed using MacroModel 9.9,18 the
OPLS-AA(2005) forceeld33 and GB/SA continuum model for
H2O solvation eﬀects.55 The conformations were then optimized
using DFT (M06-2X/6-31+G*) with Jaguar 8.0 (ref. 18) and8 | Med. Chem. Commun., 2014, xx, 1–10frequency calculations used to characterize the stationary
points as true minima, as well as for calculation of the gas-
phase Gibbs free energies at 298.15 K. For the solution phase
QM calculations (M06-2X/cc-pVTZ++)22 at these geometries, a
SCRF continuum treatment of solvation with the PBF equation
was used.24,25
Protein preparation. The initial setup of the GPb receptor for
calculations was performed using Schrodinger's “Protein Prep-
aration Wizard”18 starting from the GPb–1b co-crystallised
complex. Water molecules were deleted, bond orders
assigned, and hydrogen atoms added, with protonation states
for basic and acidic residues based on residue pKa values at
normal pH (7.0). Subsequent optimization of hydroxyl groups,
histidine protonation states and C/N atom “ips”, and side-
chain O/N atom ips of Asn and Gln was based on optimizing
hydrogen bonding patterns. The phosphate in pyridoxal-
phosphate (PLP) was assigned in monoanionic form. Finally,
an “Impref” minimization of the GPb complex was performed
using the OPLS-AA(2005) force eld33 to remove steric clashes
and bad contacts but with heavy atoms constrained to within
0.3 A˚ (RMSD) of their crystallographic positions.
Docking details. For the Glide 5.8 docking calculations in
extra-precision (XP) mode, the shape and properties of the GPb
catalytic binding site were rst mapped onto grids with
dimensions of 26.7  26.7  26.7 A˚ centered on the native co-
crystallized ligand (1b). Core constraints (1 A˚) on the six glucose
ring atoms + the ligands' amide moieties to retain them close to
the native ligand crystallographic positions were applied. Post-
docking minimization of the ligand poses was performed (with
strain correction) with a maximum of 5 poses per ligand saved.
Poses were considered conformationally distinct for RMSDs
(heavy atoms) > 0.5 A˚.Synthesis
The general procedures employed for the synthesis are
described in the ESI,† together with the NMR data.GP inhibition assay
Glycogen phosphorylase b was prepared from rabbit skeletal
muscle according to the method of Fischer and Krebs56 using 2-
mercaptoethanol instead of L-cysteine, and recrystallized at
least three times before use. The kinetic studies with glycogen
phosphorylase were performed as described previously.46
Kinetic data for the inhibition of rabbit skeletal muscle
glycogen phosphorylase by monosaccharide compounds were
collected using diﬀerent concentrations of a-D-glucose-1-
phosphate (4, 6, 8, 10, 12 and 14 mM) and constant concen-
trations of glycogen (1% w/v) and AMP (1 mM). The enzymatic
activities were presented in the form of double-reciprocal plots
(Lineweaver–Burk) applying a nonlinear data-analysis pro-
gramme. The inhibitor constants (Ki) were determined by Dixon
plots, by replotting the slopes from the Lineweaver–Burk plots
against the inhibitor concentrations. The means of standard
errors for all calculated kinetic parameters averaged to less than
10%.3,57 IC50 values were determined in the presence of 4 mMThis journal is © The Royal Society of Chemistry 2014
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1glucose 1-phosphate, 1 mM AMP, 1% glycogen, and varying
concentrations of an inhibitor.5
10
15
20
25
30Conclusions
Molecular modeling investigations in the form of docking, QM
and QM/MM studies has motivated the experimental evaluation
of N-(b-D-glucopyranosyl)-1,2,4-triazolecarboxamides as GP
inhibitors. The value of QM calculations to determine favorable
tautomeric states is highlighted, while QM/MM optimizations
were used to decipher the more likely binding interactions in
the absence of time consuming X-ray crystallographic evidence.
While there is oen uncertainty in assigning hydrogen posi-
tions using crystallography,58 QM/MM calculations allowed us
to accurately consider the binding potential of the diﬀerent 5a-
5c 1,2,4-triazole tautomers, with the GPb interactions formed by
the most stable t2 tautomer and its conformational exibility
deemed signicant. Synthesis, followed by kinetics experiments
revealed 5a,b as low mM inhibitors of GP, with 5a the in the top
10 most potent catalytic site inhibitor discovered to date.4 The
N-(b-D-glucopyranosyl)-1,2,4-triazolecarboxamides are predicted
to have drug-like potential, but with permeability a potential
issue to eﬃcacy. While intra-molecular bonding has the
potential to improve membrane permeability by reducing the
polar surface areas,52 this eﬀect is likely to be minimal in our
case. However, glucose analogues have already demonstrated
blood glucose lowering eﬀects in vivo,10,11 a large number of
triazole compounds are found as clinical drugs or candidates
for treatment of a range of diseases,59 so that we consider the
ligands studied worthy candidates for further optimization
studies. Finally, the value of a computationally lead approach to
GP inhibitor design has been highlighted in this work.2735
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